Search Result

Results for "

leukotriene D4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Leukotriene Receptor (27) Drug Isomer (1) Drug Metabolite (2) Endogenous Metabolite (5) Histamine Receptor (2) Isotope-Labeled Compounds (5) LPL Receptor (2) P-glycoprotein (2) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (3) PROTAC Linkers (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Endocrinology (3) Inflammation/Immunology (28) Metabolic Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Leukotriene Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113456

Leukotriene D4	Drug Metabolite Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Leukotriene D4 is a potent bronchoconstrictor. Leukotriene D4 has the potential for the research of asthma. Leukotriene D4 induces edema and increases capillary permeability .

HY-113456S

Leukotriene D4-d5	Drug Metabolite Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Leukotriene D4-d₅ is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.

HY-107610

SR2640 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
SR2640 (hydrochloride) is a potent and selective competitive leukotriene D4/leukotriene E4 antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma .

HY-U00253

KP496	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.

HY-137493

*14,15-Leukotriene* D4** 14,15-LTD4; Eoxin D4	Endogenous Metabolite	Inflammation/Immunology
14,15-Leukotriene D4 (14,15-LTD4) is a leukotriene that producted by eosinophils with Arachidonic acid (HY-109590), and through the 15-lipoxygenase-1 pathway .

HY-W747563

*11-trans Leukotriene* D4** 11-trans LTD4	Drug Isomer	Others
11-trans Leukotriene D4 (11-trans LTD4) is a C-11 double bond isomer of LTD4. LTD4 undergoes slow temperature-dependent isomerization to 11-trans LTD4 during storage. 11-trans LTD4 retains about 10-25 % of the potency for contraction of guinea pig ileum, trachea and parenchyma compared to LTD4. It exhibits an ED50 ranging between 12-60 nM for contraction of guinea pig trachea.

HY-107608S

Leukotriene B4-d4 LTB4-d₄; 5(S),12(R)-DiHETE-d₄	PROTAC Linkers Endogenous Metabolite Leukotriene Receptor	Inflammation/Immunology Cancer
Leukotriene B4-d₄ is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2][3].

HY-168784

LTD4 antagonist 2	Leukotriene Receptor	Metabolic Disease Inflammation/Immunology
LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC₅₀ of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-113693

ONO-RS-347	Leukotriene Receptor	Others
ONO-RS-347 is an orally active and potent antagonist of leukotriene C4 and D4. ONO-RS-347 inhibits LTD4-induced bronchoconstriction in guinea pigs. ONO-RS-347 is promising for research of allergic asthma and other immediate hypersensitivty diseases .

HY-116326

BayCysLT2	Leukotriene Receptor	Inflammation/Immunology
BayCysLT2, an isophthalic acid derivative, is a selective and potent cysteinyl leukotriene 2 (CysLT2) receptor antagonist with an IC₅₀ value of 53 nM. BayCysLT2 inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. BayCysLT2 reverses LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts .

HY-105221

Masilukast ZD-3523	Leukotriene Receptor	Inflammation/Immunology
Masilukast is an orally administered *cysteinyl leukotriene* D₄ (LTD₄) receptor** antagonist with potential to research asthma.

HY-U00359

LTD4 antagonist 1	Leukotriene Receptor	Inflammation/Immunology
LTD₄ antagonist 1 is a potent, orally active antagonist of leukotriene D₄ (LTD₄) with a K_i of 0.57 nM.

HY-111212

Tomelukast LY171883	Leukotriene Receptor	Inflammation/Immunology
Tomelukast (LY171883) is an orally active leukotriene D₄ and E₄ antagonist. Tomelukast can be used for the research of asthma .

HY-122149

L-648051	Leukotriene Receptor	Cardiovascular Disease
L-648051 is a leukotriene D4 receptor (LTD4) antagonist. L-648051 plays an important role in arrhythmias .

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-100316

CP-96486	Leukotriene Receptor	Inflammation/Immunology
CP-96486 is a potent and orally active leukotriene D₄ (LTD₄)/platelet activating factor (PAF) receptor antagonist with K_is of 20 and 24 nM, respectively.

HY-101731

CP-96021 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with K_i values of 34 nM and 37 nM, respectively .

HY-17492S

Zafirlukast-d7	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].

HY-17492S3

Zafirlukast-d6 ICI 204219-d₆	Leukotriene Receptor Isotope-Labeled Compounds	Inflammation/Immunology Cancer
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492R

Zafirlukast (Standard)	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6 ICI 204219-¹³C,d₆	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3 ICI 204219-¹³C,d₃	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-120755

LY290324	Leukotriene Receptor	Inflammation/Immunology
LY290324 is a potent and orally active leukotriene D4 (LTD4) antagonist. LY290324 reduces LTC4, LTD4 and LTE4 (HY-113465)-induced bronchospasm. LY290324 has the potential for the research of antigen-induced bronchospasm .

HY-U00364

CI-949	Histamine Receptor Prostaglandin Receptor Leukotriene Receptor	Inflammation/Immunology Endocrinology
CI-949 is an allergic mediator release inhibitor, which inhibits histamine, leukotriene C₄/D₄ (LTC₄/LTD₄), and thromboxane B₂ (TXB₂) release with IC₅₀s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.

HY-113758

LY 163443	Leukotriene Receptor	Inflammation/Immunology
LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4). LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4 .

HY-117842

KY 234	Histamine Receptor	Inflammation/Immunology
KY 234 is an orally effective inhibitor that targets thromboxane A2 production, with an IC₅₀ of 5 μM. KY 234 significantly inhibits leukotriene D4 (LTD4), histamine, and antigen-induced bronchoconstriction in guinea pigs, with IC₅₀ values of 6.0 mg/kg, 2.5 mg/kg, and 6.3 mg/kg, respectively .

HY-B0290S1

Pranlukast-d4 ONO-1078-d₄	Isotope-Labeled Compounds Leukotriene Receptor Endogenous Metabolite	Inflammation/Immunology
Pranlukast-d₄ is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

HY-19989

MK-571 Maximum Cited Publications 27 Publications Verification L-660711	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-19109

RG-7152	Leukotriene Receptor	Others
RG-7152 is a tetrazolyl-substituted leukotriene D4 receptor antagonist that can induce peroxisomal β-oxidation and peroxisome bifunctional enzymes (PBEs) in hepatocytes in various animal models. It has been shown to significantly increase PBE levels and β-oxidation activity in rat and mouse liver homogenates, while smaller effects were observed in guinea pigs and monkeys and no effect in dogs. In vitro studies have also shown that it can induce PBEs comparable to clofibric acid, indicating its potential as a peroxisome proliferator .

HY-19989A

MK-571 sodium Maximum Cited Publications 27 Publications Verification L-660711 sodium	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-163101

CP-96021	Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor	Inflammation/Immunology
CP-96021 is a potent and orally available leukotriene D₄ (LTD₄ K_i=34 μM) / platelet activating factor (PAF K_i=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD₄ and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC₅₀ values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113456

Leukotriene D4	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Drug Metabolite Endogenous Metabolite
Leukotriene D4 is a potent bronchoconstrictor. Leukotriene D4 has the potential for the research of asthma. Leukotriene D4 induces edema and increases capillary permeability .

Cat. No.	Product Name	Chemical Structure

HY-113456S

Leukotriene D4-d5
Leukotriene D4-d₅ is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.

Leukotriene D4-d5

Leukotriene D4-d₅ is the deuterium labeled Leukotriene D4. Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity.

HY-107608S

Leukotriene B4-d4
Leukotriene B4-d₄ is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2][3].

HY-17492S

Zafirlukast-d7
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects[1][2].

HY-17492S3

Zafirlukast-d6
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-B0290S1

Pranlukast-d4
Pranlukast-d₄ is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

leukotriene D4

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products